Caligor Rx Becomes Corporate Alliance Member of Global Genes™

SECAUCUS, N.J.--()--Caligor Rx, a global leader in pharmaceutical sourcing and supply for clinical trials and Global Access Programs, today announced that it has partnered with Global Genes™, a leading rare disease patient advocacy organization.

Caligor Rx will participate as a member of Global Genes’ 2015 RARE Corporate Alliance™. The mission of the Alliance is to combine the resources of industry and patient communities to improve health and expedite access to effective therapies for patients with rare diseases.

“Caligor Rx is proud to become a Corporate Alliance member of Global Genes and participate in the organization’s mission to help provide critical connections and resources to the estimated 350 million people affected by rare diseases worldwide,” said Tammy Bishop, the Company’s managing director. “Global Genes is dedicated to addressing the unmet medical needs of rare disease patients, and our employees embrace the opportunity to share in that commitment.”

Through its Global Access Programs (GAP), Caligor Rx is helping to provide access to investigational medicines for patients with serious or life-threatening diseases and conditions in situations where no comparable treatment option exists in the patient’s own country.

“Of the nearly 7,000 identified rare diseases, fewer than 400 have FDA-approved drug treatments, so it’s critically important to support the Global Genes mission to help physicians, patients, care givers and advocates become activists in finding innovative treatment options for these rare conditions,” Bishop said. “Global Access Programs provide controlled, compliant and ethical access to unlicensed medicines for patients with rare diseases, while giving pharmaceutical companies real-world data that can support further clinical development and, ultimately, commercialization.”

About Global Genes

Global Genes™ is a leading rare disease patient advocacy organization. The group’s mission is to eliminate the challenges of rare disease by providing patients with educational tools, building awareness, providing critical connections to people and resources, and through investment in technologies that will positively impact affected patients and families. Recognized worldwide by the Blue Denim Genes Ribbon™, Global Genes unites experts, advocates and patients of all ages to stand together in hope for treatments and cures for the estimated 7,000 rare and genetic diseases that impact approximately 35 million Americans and over 350 million people worldwide. For more information about Global Genes, please visit http://globalgenes.org/

About Caligor Rx

Caligor Rx strives to be the premier provider of pharmaceutical services that enable our clients to improve patients’ lives through effective, cost-efficient clinical trials and Global Access Programs. Regulatory knowledge, strong expertise in managing unlicensed medicines and a commitment to the highest ethical standards provide the foundation for everything we do. The consistent strategic value we deliver as a supply chain partner gives our clients the freedom to focus on the essence of life sciences – delivering quality outcomes. Certified by the Women’s Business Enterprise National Council as a Woman-Owned Business, Caligor Rx is licensed to distribute approved and unlicensed medicines in the continental United States and throughout Europe. Information about the Company’s services is available at www.caligorrx.com.

Contacts

Sharon Merrill Associates, Inc.
Scott Solomon, 617-542-5300
ssolomon@investorrelations.com

Contacts

Sharon Merrill Associates, Inc.
Scott Solomon, 617-542-5300
ssolomon@investorrelations.com